title: AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation--treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A.
abstract: Plasmablastic lymphoma is an AIDS related lymphoma that continues to have a poor prognosis despite significant advances in the management of HIV and lymphoproliferative diseases. In part this has been due to limited insights into the biology of this disease and the molecular mechanisms of oncogenesis. To date molecular abnormalities have not been described in plasmablastic lymphoma, and its aggressive clinical behaviour has been difficult to understand. We describe the first reported cytogenetic abnormality in plasmablastic lymphoma, an IgH/MYC translocation. It is also the first description of autologous stem cell transplantation in a patient with severe haemophilia A.
authors.affiliation: Clinical Haematology/Bone Marrow Transplant Department, The Alfred, Commercial Road, Prahran, Melbourne, Victoria, Australia. dawsonm@ausdoctors.net
authors.forename: Mark A
authors.initials: MA
authors.lastname: Dawson
authors.forename: Anthony P
authors.initials: AP
authors.lastname: Schwarer
authors.forename: Catriona
authors.initials: C
authors.lastname: McLean
authors.forename: Paul
authors.initials: P
authors.lastname: Oei
authors.forename: Lynda J
authors.initials: LJ
authors.lastname: Campbell
authors.forename: Edwina
authors.initials: E
authors.lastname: Wright
authors.forename: Jake
authors.initials: J
authors.lastname: Shortt
authors.forename: Alison M
authors.initials: AM
authors.lastname: Street
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D002883:Chromosomes, Human, Pair 14 / Q000235:genetics / Q000648:ultrastructure*; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics / Q000648:ultrastructure*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D020031:Epstein-Barr Virus Infections / Q000150:complications; D017809:Fatal Outcome; D016259:Genes, myc; D005887:Gingival Neoplasms / Q000150:complications / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D006467:Hemophilia A / Q000150:complications* / Q000628:therapy; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics*; D016483:Lymphoma, AIDS-Related / Q000150:complications / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D016400:Lymphoma, Large-Cell, Immunoblastic / Q000150:complications / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D008297:Male; D036102:Peripheral Blood Stem Cell Transplantation; D011241:Prednisone / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D014178:Translocation, Genetic; D014182:Transplantation, Autologous; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D007143:Immunoglobulin Heavy Chains; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone